Meropenem Actavis

Meropenem, the active ingredient in Meropenem Actavis, is a carbapenem presented as an injectable solution for intravenous use. It treats severe bacterial infections such as complicated intra‑abdominal infections, urinary tract infections, bacterial meningitis, severe sepsis, hospital‑acquired pneumonia, and complicated skin and soft tissue infections in hospitalized patients.

GNH USA supplies Meropenem Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Meropenem is a broad‑spectrum carbapenem antibiotic used to treat serious bacterial infections. - Complicated intra‑abdominal infections: provides bactericidal activity against mixed aerobic and anaerobic pathogens. - Complicated urinary tract infections: eradicates resistant Gram‑negative organisms causing severe UTIs. - Bacterial meningitis: penetrates the cerebrospinal fluid to treat meningitis caused by susceptible bacteria. - Severe sepsis and septic shock: rapidly reduces bacterial load in systemic infections. - Hospital‑acquired pneumonia: covers typical and atypical pathogens in ventilated patients. - Complicated skin and soft tissue infections: treats resistant Staphylococcus and Gram‑negative infections.

Adverse reactions to Meropenem may vary in frequency and severity.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: loose stools. - Headache: transient cranial discomfort. - Injection site pain: discomfort during infusion.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction. - Seizures: risk in patients with renal impairment or CNS disorders. - Clostridioides difficile colitis: severe intestinal infection. - Stevens‑Johnson syndrome: rare mucocutaneous reaction.

When using Meropenem, consider the following precautions. - Renal function: adjust dose in patients with impaired renal clearance. - Hypersensitivity: avoid in individuals with known carbapenem or β‑lactam allergy. - CNS disorders: monitor for seizures, especially in patients with pre‑existing neurological disease. - Pregnancy and lactation: use only if benefits outweigh potential risks, as safety data are limited. - Concomitant nephrotoxic drugs: monitor renal parameters when combined with aminoglycosides or vancomycin. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may interact with other medicines; awareness of major and moderate interactions is important.

Major Interactions (Avoid): - Valproic acid: may reduce serum valproate levels, risking seizure breakthrough. - High‑dose aminoglycosides: increased risk of nephrotoxicity. - Loop diuretics: may exacerbate electrolyte disturbances. - Probenecid: can increase meropenem plasma concentrations, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect; monitor INR. - Rifampin: may lower meropenem levels; consider dose adjustment. - Oral contraceptives: potential reduction in efficacy; advise alternative contraception.